Investor Presentaiton

Daprodustat Potential best-in-class treatment for patients with anaemia due to CKD1 Nobel prize-winning science with OH OH Pro Pro NORMOXIA PATHWAY HIFa Asm Daprodustat (HIF-PHI) HIF Prolyl Hydroxylase-1,2,3 Enzyme Pro Pro HIFG Asn HYPOXIA PATHWAY Pro Pro Ubiquitin- mediated degredation of HIFa Nucleus HiFa Asni Transcription of HIF-responsive genes HIFE 300 Moni ASCEND2: Phase III clinical development programme with large geographical reach • • >8,000 patients with anaemia due to CKD3 in five Phase III trials Consistent clinical trial programme: • Active control (injectable ESA4) • One global Hb5 target range (10-11 g/dl) • Standardised patient management methods6 • Trial design and primary MACE7 end-point aligned with global regulators • No meta-analysis required •Studies in dialysis (peritoneal, and haemodialysis) and non-dialysis High unmet medical need gsk >700 million people suffer from chronic kidney disease worldwide 0000000 One in seven patients suffer from anaemia of CKD where the current standard of care is administered via subcutaneous injection or as part of dialysis 1. Chronic kidney disease 2. Anaemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat 3. Presented at American Society of Nephrology Kidney Week 2021: Singh AK, et al. FR-OR66 and PO0465; Coyne DM, et al PO0487; and Johensen KL, et al FR-CR53 4. Erythropoiesis-stimulating agents 5. Haemoglobin 6. Dose adjustment algorithms, iron management criteria and anaemia rescue algorithms 7. Evaluating a composite of all-cause mortality, stroke and myocardial infarction 8. The Lancet, The Global Burden of Chronic Kidney Disease published in February 2020. 6

View entire presentation